# Alcoa Corp: financial statements, quarterly

AA · NYSE · CIK 1675149 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aa.md) · [Financials](/companies/aa/financials.md) · [Filings](/companies/aa/filings.md) · [Insiders](/companies/aa/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aa/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,595 d](/filings/0001193125-26-077167.md) | [2,599](/filings/0000950170-25-061867.md) | [2,906](/filings/0000950170-25-100979.md) | [2,904](/filings/0001193125-25-253570.md) | [3,486 d](/filings/0001193125-26-077167.md) | [3,369](/filings/0001193125-26-197447.md) | [3,018](/filings/0001193125-26-326265.md) | [2,995](/filings/0001193125-26-437885.md) | [3,449 d](/filings/0001193125-26-077167.md) | [3,193](/filings/0001193125-26-197447.md) | [3,966](/filings/0001193125-26-326265.md) | [3,704](/filings/0001193125-26-437885.md) |
| Research and development | $m | [14.0 d](/filings/0001193125-26-077167.md) | [11.0](/filings/0000950170-25-061867.md) | [13.0](/filings/0000950170-25-100979.md) | [16.0](/filings/0001193125-25-253570.md) | [17.0 d](/filings/0001193125-26-077167.md) | [12.0](/filings/0001193125-26-197447.md) | [12.0](/filings/0001193125-26-326265.md) | [11.0](/filings/0001193125-26-437885.md) | [(11.0) d](/filings/0001193125-26-077167.md) | [10.0](/filings/0001193125-26-197447.md) | [11.0](/filings/0001193125-26-326265.md) | [8.0](/filings/0001193125-26-437885.md) |
| Selling, general and administrative | $m | [64.0 d](/filings/0001193125-26-077167.md) | [60.0](/filings/0000950170-25-061867.md) | [69.0](/filings/0000950170-25-100979.md) | [66.0](/filings/0001193125-25-253570.md) | [80.0 d](/filings/0001193125-26-077167.md) | [71.0](/filings/0001193125-26-197447.md) | [82.0](/filings/0001193125-26-326265.md) | [78.0](/filings/0001193125-26-437885.md) | [68.0 d](/filings/0001193125-26-077167.md) | [83.0](/filings/0001193125-26-197447.md) | [101](/filings/0001193125-26-326265.md) | [97.0](/filings/0001193125-26-437885.md) |
| Interest expense | $m | [28.0 d](/filings/0001193125-26-077167.md) | [27.0](/filings/0000950170-25-061867.md) | [40.0](/filings/0000950170-25-100979.md) | [44.0](/filings/0001193125-25-253570.md) | [45.0 d](/filings/0001193125-26-077167.md) | [53.0](/filings/0001193125-26-197447.md) | [56.0](/filings/0001193125-26-326265.md) | [33.0](/filings/0001193125-26-437885.md) | [16.0 d](/filings/0001193125-26-077167.md) | [35.0](/filings/0001193125-26-197447.md) | [36.0](/filings/0001193125-26-326265.md) | [42.0](/filings/0001193125-26-437885.md) |
| Income tax | $m | [(36.0)](/filings/0000950170-24-018069.md) | [(18.0)](/filings/0000950170-25-061867.md) | [61.0](/filings/0000950170-25-100979.md) | [86.0](/filings/0001193125-25-253570.md) | [136 d](/filings/0001193125-26-077167.md) | [120](/filings/0001193125-26-197447.md) | [10.0](/filings/0001193125-26-326265.md) | [(51.0)](/filings/0001193125-26-437885.md) | [(134) d](/filings/0001193125-26-077167.md) | [82.0](/filings/0001193125-26-197447.md) | [73.0](/filings/0001193125-26-326265.md) | [91.0](/filings/0001193125-26-437885.md) |
| Net income | $m | [(150) d](/filings/0001193125-26-077167.md) | [(252)](/filings/0000950170-25-061867.md) | [20.0](/filings/0000950170-25-100979.md) | [90.0](/filings/0001193125-25-253570.md) | [202 d](/filings/0001193125-26-077167.md) | [548](/filings/0001193125-26-197447.md) | [164](/filings/0001193125-26-326265.md) | [232](/filings/0001193125-26-437885.md) | [213 d](/filings/0001193125-26-077167.md) | [425](/filings/0001193125-26-197447.md) | [407](/filings/0001193125-26-326265.md) | [483](/filings/0001193125-26-437885.md) |
| Diluted EPS | $ per share | not reported | [(1.41)](/filings/0000950170-25-061867.md) | [0.11](/filings/0000950170-25-100979.md) | [0.38](/filings/0001193125-25-253570.md) | not reported | [2.07](/filings/0001193125-26-197447.md) | [0.62](/filings/0001193125-26-326265.md) | [0.88](/filings/0001193125-26-437885.md) | not reported | [1.60](/filings/0001193125-26-197447.md) | [1.53](/filings/0001193125-26-326265.md) | [1.81](/filings/0001193125-26-437885.md) |
| Basic EPS | $ per share | not reported | [(1.41)](/filings/0000950170-25-061867.md) | [0.11](/filings/0000950170-25-100979.md) | [0.39](/filings/0001193125-25-253570.md) | not reported | [2.08](/filings/0001193125-26-197447.md) | [0.63](/filings/0001193125-26-326265.md) | [0.88](/filings/0001193125-26-437885.md) | not reported | [1.61](/filings/0001193125-26-197447.md) | [1.54](/filings/0001193125-26-326265.md) | [1.83](/filings/0001193125-26-437885.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.9](/filings/0000950170-25-024242.md) | [1.4](/filings/0000950170-24-052174.md) | [1.4](/filings/0000950170-24-090092.md) | [1.3](/filings/0000950170-24-119557.md) | [1.1](/filings/0001193125-26-077167.md) | [1.2](/filings/0000950170-25-061867.md) | [1.5](/filings/0000950170-25-100979.md) | [1.5](/filings/0001193125-25-253570.md) | [1.6](/filings/0001193125-26-437885.md) | [1.4](/filings/0001193125-26-197447.md) | [1.4](/filings/0001193125-26-326265.md) | [4.4](/filings/0001193125-26-437885.md) |
| Current assets | $bn | [4.4](/filings/0000950170-25-024242.md) | [4.9](/filings/0000950170-24-052174.md) | [4.9](/filings/0000950170-24-090092.md) | [4.9](/filings/0000950170-24-119557.md) | [4.9](/filings/0001193125-26-077167.md) | [5.2](/filings/0000950170-25-061867.md) | [5.4](/filings/0000950170-25-100979.md) | [5.3](/filings/0001193125-25-253570.md) | [5.5](/filings/0001193125-26-437885.md) | [5.7](/filings/0001193125-26-197447.md) | [5.9](/filings/0001193125-26-326265.md) | [9.2](/filings/0001193125-26-437885.md) |
| Total assets | $bn | [14.2](/filings/0000950170-25-024242.md) | [14.3](/filings/0000950170-24-052174.md) | [14.3](/filings/0000950170-24-090092.md) | [14.5](/filings/0000950170-24-119557.md) | [14.1](/filings/0001193125-26-077167.md) | [14.6](/filings/0000950170-25-061867.md) | [15.0](/filings/0000950170-25-100979.md) | [16.0](/filings/0001193125-25-253570.md) | [16.1](/filings/0001193125-26-437885.md) | [16.6](/filings/0001193125-26-197447.md) | [16.9](/filings/0001193125-26-326265.md) | [20.4](/filings/0001193125-26-437885.md) |
| Current liabilities | $bn | [3.0](/filings/0000950170-25-024242.md) | [3.0](/filings/0000950170-24-052174.md) | [3.2](/filings/0000950170-24-090092.md) | [3.5](/filings/0000950170-24-119557.md) | [3.4](/filings/0001193125-26-077167.md) | [3.0](/filings/0000950170-25-061867.md) | [3.3](/filings/0000950170-25-100979.md) | [3.4](/filings/0001193125-25-253570.md) | [3.8](/filings/0001193125-26-437885.md) | [3.8](/filings/0001193125-26-197447.md) | [3.8](/filings/0001193125-26-326265.md) | [4.0](/filings/0001193125-26-437885.md) |
| Total liabilities | $bn | [8.3](/filings/0000950170-25-024242.md) | [8.8](/filings/0000950170-24-052174.md) | [8.9](/filings/0000950170-24-090092.md) | [9.3](/filings/0000950170-24-119557.md) | [8.9](/filings/0001193125-26-077167.md) | [8.7](/filings/0000950170-25-061867.md) | [8.8](/filings/0000950170-25-100979.md) | [9.5](/filings/0001193125-25-253570.md) | [9.9](/filings/0001193125-26-437885.md) | [9.7](/filings/0001193125-26-197447.md) | [9.4](/filings/0001193125-26-326265.md) | [12.1](/filings/0001193125-26-437885.md) |
| Long-term debt | $bn | [1.7](/filings/0000950170-25-024242.md) | not reported | not reported | not reported | [2.5](/filings/0001193125-26-077167.md) | not reported | not reported | not reported | [2.4](/filings/0001193125-26-077167.md) | not reported | not reported | not reported |
| Current portion of debt | $bn | [0.1](/filings/0000950170-25-024242.md) | not reported | not reported | not reported | [0.1](/filings/0001193125-26-077167.md) | not reported | not reported | not reported | [0.0](/filings/0001193125-26-077167.md) | not reported | not reported | not reported |
| Short-term borrowings | $bn | [0.1](/filings/0000950170-25-024242.md) | [0.1](/filings/0000950170-24-052174.md) | [0.0](/filings/0000950170-24-090092.md) | [0.0](/filings/0000950170-24-119557.md) | [0.1](/filings/0001193125-26-077167.md) | [0.0](/filings/0000950170-25-061867.md) | [0.0](/filings/0000950170-25-100979.md) | [0.0](/filings/0001193125-25-253570.md) | [0.0](/filings/0001193125-26-437885.md) | [0.1](/filings/0001193125-26-197447.md) | [0.0](/filings/0001193125-26-326265.md) | [0.0](/filings/0001193125-26-437885.md) |
| Shareholders' equity | $bn | [4.3](/filings/0000950170-25-024242.md) | [4.0](/filings/0000950170-24-052174.md) | [3.9](/filings/0000950170-24-090092.md) | [5.3](/filings/0000950170-24-119557.md) | [5.2](/filings/0000950170-25-024242.md) | [5.8](/filings/0001193125-26-437885.md) | [6.1](/filings/0001193125-26-437885.md) | [6.3](/filings/0001193125-26-437885.md) | [6.1](/filings/0001193125-26-437885.md) | [6.8](/filings/0001193125-26-437885.md) | [7.4](/filings/0001193125-26-437885.md) | [8.2](/filings/0001193125-26-437885.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [198 d](/filings/0001193125-26-077167.md) | [(223)](/filings/0000950170-25-061867.md) | [287 d](/filings/0000950170-25-100979.md) | [143 d](/filings/0001193125-25-253570.md) | [415 d](/filings/0001193125-26-077167.md) | [75.0](/filings/0001193125-26-197447.md) | [488 d](/filings/0001193125-26-326265.md) | [85.0 d](/filings/0001193125-26-437885.md) | [537 d](/filings/0001193125-26-077167.md) | [(179)](/filings/0001193125-26-197447.md) | [608 d](/filings/0001193125-26-326265.md) | [643 d](/filings/0001193125-26-437885.md) |
| Capital expenditure | $m | [188 d](/filings/0001193125-26-077167.md) | [101](/filings/0000950170-25-061867.md) | [164 d](/filings/0000950170-25-100979.md) | [146 d](/filings/0001193125-25-253570.md) | [169 d](/filings/0001193125-26-077167.md) | [93.0](/filings/0001193125-26-197447.md) | [131 d](/filings/0001193125-26-326265.md) | [151 d](/filings/0001193125-26-437885.md) | [243 d](/filings/0001193125-26-077167.md) | [119](/filings/0001193125-26-197447.md) | [186 d](/filings/0001193125-26-326265.md) | [171 d](/filings/0001193125-26-437885.md) |
| Dividends paid | $m | [18.0 d](/filings/0001193125-26-077167.md) | [19.0](/filings/0000950170-25-061867.md) | [18.0 d](/filings/0000950170-25-100979.md) | [26.0 d](/filings/0001193125-25-253570.md) | [26.0 d](/filings/0001193125-26-077167.md) | [26.0](/filings/0001193125-26-197447.md) | [26.0 d](/filings/0001193125-26-326265.md) | [26.0 d](/filings/0001193125-26-437885.md) | [26.0 d](/filings/0001193125-26-077167.md) | [27.0](/filings/0001193125-26-197447.md) | [26.0 d](/filings/0001193125-26-326265.md) | [27.0 d](/filings/0001193125-26-437885.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: not reported

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [178](/filings/0000950170-24-052174.md) | [178](/filings/0000950170-24-090092.md) | [178](/filings/0000950170-24-119557.md) | [179](/filings/0000950170-25-061867.md) | [181](/filings/0000950170-25-100979.md) | [234](/filings/0001193125-25-253570.md) | [260](/filings/0001193125-26-197447.md) | [260](/filings/0001193125-26-326265.md) | [261](/filings/0001193125-26-437885.md) | [266](/filings/0001193125-26-197447.md) | [266](/filings/0001193125-26-326265.md) | [266](/filings/0001193125-26-437885.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 263,969,874 at 2026-10-26, from the cover of the [10-Q filed 2026-10-29](/filings/0001193125-26-437885.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 18:58 ET. No prices; not investment advice.